Continuous positive airway pressure

Four Independent Scientific Abstracts at the American Academy of Dental Sleep Medicine Annual Meeting Feature ProSomnus Intraoral Medical Devices

Retrieved on: 
Thursday, May 9, 2024
University, OAT, Political moderate, Splint (medicine), ENT, CPAP, University of Antwerp, MD, Research, First Line, Dentist, Continuous positive airway pressure, Obstructive sleep apnea, Sleep apnea, Telehealth, Faculty, AHI, Comparison, OSA, Neuroscience, Pharmaceutical industry

1Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; 2Department of ENT, Head and Neck Surgery, Antwerp University Hospital, Edegem, Belgium.

Key Points: 
  • 1Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; 2Department of ENT, Head and Neck Surgery, Antwerp University Hospital, Edegem, Belgium.
  • The data from the FLOSAT study indicate that OSA therapy with ProSomnus EVO devices is safe, effective, and better adhered to than CPAP.
  • BlueSleep, the leader in virtual diagnosis and treatment of sleep apnea, is presenting results of two studies at the 2024 AADSM Annual Meeting.
  • In a second study, BlueSleep compared the initial fitting of ProSomnus devices either in a virtual or in-person workflow.

Global Sleep Apnea Devices Analysis Report 2024: Market to Surpass $9.95 Billion by 2030, China Emerges as a Sleep Apnea Devices Powerhouse - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 9, 2024
Medical Devices, Health, Telehealth, MHealth, Sleep, Continuous positive airway pressure, Knowledge, Obesity, Sleep apnea, Incidence, Ageing, CPAP, Prevalence, Strategic planning, Pharmaceutical industry

Global sleep apnea devices market will reach a value of US$ 9.95 billion by 2030, expanding at a CAGR of 7.34% from 2024 to 2030.

Key Points: 
  • Global sleep apnea devices market will reach a value of US$ 9.95 billion by 2030, expanding at a CAGR of 7.34% from 2024 to 2030.
  • The sleep apnea devices market is categorized into therapeutic and diagnostic devices.
  • Globally, the market study encompasses various regions, with China forecasted to exhibit robust growth within the Asia-Pacific market for sleep apnea devices.
  • As sleep apnea continues to affect individuals globally, this report shines a light on the vital role of sleep apnea devices in managing this pervasive condition.

CPAP Liquidators Introduces Enhanced Travel CPAP Solutions for Sleep Apnea Patients Nationwide

Retrieved on: 
Thursday, April 11, 2024
Travel, Flexible, Health, Life, Continuous positive airway pressure, Flexible spending account, FSA, Sleep apnea, Pressure, Patient, Health savings account, Work, HSA, Transcend, Sleep, CPAP, Pharmaceutical industry

WALNUT GROVE, Minn., April 11, 2024 /PRNewswire/ -- CPAP Liquidators, a leading supplier of CPAP equipment, is thrilled to unveil an expanded lineup of travel CPAP machines, catering to the needs of sleep apnea patients seeking convenient and reliable therapy options on the go.

Key Points: 
  • WALNUT GROVE, Minn., April 11, 2024 /PRNewswire/ -- CPAP Liquidators, a leading supplier of CPAP equipment, is thrilled to unveil an expanded lineup of travel CPAP machines, catering to the needs of sleep apnea patients seeking convenient and reliable therapy options on the go.
  • An essential aspect of CPAP Liquidators' travel CPAP solutions is their compatibility with Flexible Spending Accounts (FSA) and Health Savings Accounts (HSA), enabling customers to utilize pre-tax funds for their sleep therapy equipment purchases.
  • This feature underscores CPAP Liquidators' commitment to affordability and accessibility, ensuring that individuals can access essential CPAP solutions without financial barriers.
  • Furthermore, CPAP Liquidators is committed to providing excellent customer service and support to all individuals who rely on CPAP therapy for their sleep apnea treatment.

Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, March 28, 2024
CARE, Sleep apnea, CPAP, Continuous positive airway pressure, Exercise, Environment, VIP, Obstructive sleep apnea, PAP, Shareholder, Webcast, Patient, DME, Sleep, DNA, ODO, AHI, Messenger, Myotherapy, Security (finance), Danaher Corporation, Clinical trial, Therapy, Annual report, Optimism, Dentist, FDA, Food, Pharmaceutical industry

LITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA in adults)), today reported financial results and operating highlights for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Importantly, Vivos believes that governmental investigations of unrelated third parties with non-FDA approved products in the sleep apnea treatment space adversely impacted new Vivos case starts and VIP enrollments during 2023.
  • Vivos’ CARE appliances include the flagship DNA oral appliance, the mRNA oral appliance and the mmRNA oral appliance.
  • Since then, we’ve received high levels of inquiries related to our Vivos CARE products that treat OSA in adults.
  • A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations .

Signifier Medical Technologies Announces Publication of a New Study Exploring Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea

Retrieved on: 
Thursday, March 7, 2024
Health, Medical Devices, Health Technology, Other Health, General Health, Research, Science, Diabetes, Freedom, CPAP, Patient satisfaction, Sleep apnea, Quality of life, Quality-adjusted life year, Treatment, Obstructive sleep apnea, Continuous positive airway pressure, Technology assessment, ICER, Prevalence, Hypertension, Life imprisonment, PAP, Patient, Canadian International Council, NMES, Signified and signifier, DRS, Health technology

Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled " Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea ."

Key Points: 
  • Signifier Medical Technologies LLC (“Signifier” or the “Company”), a Boston-based medical technology company, announces that The International Journal of Technology Assessment in Health Care has recently published an exploratory analysis entitled " Cost-Effectiveness of Neuromuscular Electrical Stimulation for the Treatment of Mild Obstructive Sleep Apnea ."
  • Shan Liu, Jan Pietzsch, and a collaborative research team explores the cost-effectiveness of using neuromuscular electrical stimulation (NMES) as a treatment option for patients with mild obstructive sleep apnea (OSA).
  • The results of the exploratory analysis indicated that neuromuscular electrical stimulation may be a cost-effective treatment option for mild OSA compared to no treatment.
  • "We are excited to see the results of this study reinforce the potential of neuromuscular electrical stimulation as a revolutionary treatment option for individuals with mild obstructive sleep apnea," states Mujtaba Chohan, Head of Finance & Chief of Staff at Signifier.

Sleep Apnea Symptoms Linked to Memory and Thinking Problems

Retrieved on: 
Monday, March 4, 2024
Social media, Nervous system, Alzheimer's disease, Boston Medical Center, CPAP, Dementia, Education, Sleep apnea, Blood, Quality of life, Thought, Sleep, Continuous positive airway pressure, Stroke, Confusion, Risk, Annual general meeting, DSM-IV codes, Migraine, AAN, Multiple sclerosis, Parkinson's disease, Memory, Concussion, MPH, Headache, Epilepsy, Brain, Research, American Academy, Pharmaceutical industry

"Our study found participants who had sleep apnea symptoms had greater odds of having memory or thinking problems."

Key Points: 
  • "Our study found participants who had sleep apnea symptoms had greater odds of having memory or thinking problems."
  • Of those with symptoms, 357 people, or 33%, reported memory or thinking problems compared to 628 people, or 20% of people without sleep apnea symptoms.
  • After adjusting for other factors that could affect memory and thinking problems, such as age, race, gender and education, researchers found that people who reported sleep apnea symptoms were about 50% more likely to also report having memory or thinking problems compared to people who did not have sleep apnea symptoms.
  • Additional studies are needed following people's sleep apnea, memory and thinking symptoms over time.

Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities

Retrieved on: 
Tuesday, February 6, 2024
CARE, Policy, AHI, Life, Splint (medicine), Nausea, Myotherapy, UnitedHealth Group, Irritation, Obstructive sleep apnea, Sleep, Nose, Patient, Safety, ResMed, FDA, CPAP, Respironics, PAP, Skin, Food, Mars, Therapy, Vomiting, Dizziness, Continuous positive airway pressure, Death, Headache, Health, Asthma, Pharmaceutical industry

In one market development, members of Vivos’ nationwide network of over 1,850 trained providers are actively treating current and former ResMed and Philips Respironics’ CPAP device users with Vivos CARE oral medical devices.

Key Points: 
  • In one market development, members of Vivos’ nationwide network of over 1,850 trained providers are actively treating current and former ResMed and Philips Respironics’ CPAP device users with Vivos CARE oral medical devices.
  • Vivos-trained providers currently treat failed HGNS cases using Vivos CARE oral medical devices and treatment plans.
  • Vivos believes most OSA patients seeking HGNS implants have high-moderate or severe OSA, leaving Vivos CARE oral medical devices as their only approved oral appliance therapy option.
  • We believe all of these factors create very significant revenue opportunities for us as we continue to spread the word about our product offerings.”

Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Retrieved on: 
Wednesday, January 17, 2024
Ageing, Patient, Research, Dronabinol, PAP, Obstructive sleep apnea, Continuous positive airway pressure, AHI, API, Risk, Positive airway pressure, IRB, Acetazolamide, CPAP, Food, OSA, Safety, Institutional review board, Pharmaceutical industry

IRB approval of the protocol is a key step in activation of clinical trial sites for the RePOSA study.

Key Points: 
  • IRB approval of the protocol is a key step in activation of clinical trial sites for the RePOSA study.
  • The approval process involves review of the research protocol, informed consent procedures, recruitment materials, and participant risk versus benefit analysis.
  • The study is designed to facilitate a seamless transition between Phase 2 and Phase 3, reducing downtime and accelerating development timelines.
  • IRB approval of the protocol allows the U.S.-based sites to proceed with site-specific approval, which is a critical step in site activation.

Woburn Dentist Treats Sleeping Disorders Using Oral Appliance Therapy

Retrieved on: 
Thursday, January 4, 2024
Headache, Stroke, FDA, Snoring, Myalgia, Patient, CPAP, Somnolence, Diabetes, Sleep apnea, Continuous positive airway pressure, Tongue, Sleep

WOBURN, Mass., Jan. 4, 2024 /PRNewswire/ -- Woburn Dentistry now offers a variety of treatment options for patients with snoring and sleep apnea disorders. Trained in dental sleep medicine and sedation, Dr. Jamie Chan offers an alternative to CPAP (continuous positive airway pressure) for patients with sleep apnea. For more information about the dental appliances the clinic offers, including custom sleep apnea appliances, please visit www.woburndentistryma.com/oral-appliance-therapy.

Key Points: 
  • Woburn Dentistry offers treatments for patients with sleep disorders and sleep apnea.
  • WOBURN, Mass., Jan. 4, 2024 /PRNewswire/ -- Woburn Dentistry now offers a variety of treatment options for patients with snoring and sleep apnea disorders.
  • Trained in dental sleep medicine and sedation, Dr. Jamie Chan offers an alternative to CPAP (continuous positive airway pressure) for patients with sleep apnea.
  • While CPAP is the most effective treatment for severe sleep apnea, oral appliance therapy is a simpler and easier FDA-approved solution for patients who cannot tolerate it.

Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update

Retrieved on: 
Tuesday, November 14, 2023
Webcast, Shareholder, DNA, Security (finance), Lincare Holdings, Therapy, Dentist, Clinical trial, DSO, Patient, Sleep apnea, SEC filing, DME, Snoring, FDA, Obstructive sleep apnea, OSA, ODO, CPAP, Danaher Corporation, AHI, Growth, Continuous positive airway pressure, VIP, Pharmaceutical industry, Cryptocurrency, Rare-earth element, Vivos, MENA

LITTLETON, Colo., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (OSA) and snoring in adults, today reported financial results and operating highlights for the third quarter and nine months ended September 30, 2023.

Key Points: 
  • Importantly, Vivos believes that governmental investigations of third parties with non-FDA approved products in the sleep apnea treatment space has adversely impacted new Vivos case starts and VIP enrollments during 2023.
  • The full 10-Q report will be available on the SEC Filings section of the Investor Relations section of Vivos’ website at https://vivos.com/investor-relations.
  • A live webcast of the conference call can be accessed on Vivos’ website at https://vivos.com/investor-relations .
  • An online archive of the webcast will be available on the Company’s website for 30 days following the call.